Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Timo Wolf
Viral Hemorrhagic Fever (VHF) with a Potential for Human-to-Human Transmission
Virale hämorrhagische Fieber (VHF) werden u.a. durch das Lassa-Virus, Ebola-Virus, Marburg-Virus und das Krim-Kongo-Virus verursacht. Dort, wo diese Viren endemisch vorkommen, verursachen sie sowohl zoonotische Einzelerkrankungen als auch epidemische Ausbrüche mit Mensch-zu-Mensch-Übertragungen und teils hoher Letalität. Letztere zählen zu den „high-consequence infectious diseases“ (HCID) und sollen hier näher betrachtet werden.
Dynamics and durability of HIV-1 neutralization are determined by viral replication - Nature Medicine
Abstract Human immunodeficiency virus type 1 (HIV-1)-neutralizing antibodies (nAbs) that prevent infection are the main goal of HIV vaccine discovery. But as no nAb-eliciting vaccines are yet available, only data from HIV-1 neutralizers—persons with HIV-1 who naturally develop broad and potent nAbs—can inform about the dynamics and durability of nAb responses in humans, knowledge which is crucial for the design of future HIV-1 vaccine regimens.
Villingen-Schwenningen-Umzugsunternehmen.de
Villingen-Schwenningen-Umzugsunternehmen.de - Friday, May 19, 2023. Submitted by Timo Wolf.
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial | Nature Cancer
Ethics and regulatory requirements This study was carried out in accordance with the Declaration of Helsinki and the International Conference on Harmonization and Good Clinical Practice (ICH-GCP) E6 (R2) guidelines. The study was approved by the Paul Ehrlich Institut (Federal Institute for Vaccines and Biomedicines) and the ethics committee of the Medical Faculty Heidelberg.
Antibody-mediated neutralization of authentic SARS-CoV-2 B.1.617 variants harboring L452R and T478K/E484Q
Alexander Wilhelm, Tuna Toptan, Christiane Pallas, Timo Wolf, Udo Goetsch, Rene Gottschalk, Maria JGT Vehreschild, Sandra Ciesek, View ORCID ProfileMarek Widera doi: https://doi.org/10.1101/2021.08.09.21261704 Abstract The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections.
Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
Highlights • First case report of coronavirus disease 2019 (COVID-19) in a multiple sclerosis patient under fingolimod treatment • The patient revealed severe bilateral interstitial pneumonia on chest CT scan, but recovered rapidly. • It is important to further investigate potential risks and therapeutic effects of fingolimod in COVID-19 patients Abstract Background : Fingolimod is used for immune therapy in patients with multiple sclerosis.
Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care
Summary Background In the current epidemic of Ebola virus disease in western Africa, many aid workers have become infected. Some of these aid workers have been transferred to specialised hospitals in Europe and the USA for intensified treatment, providing the potential for unique insight into the clinical course of Ebola virus disease under optimised supportive measures in isolation units.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Timo
Contact Timo, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack